PMID- 34297879
OWN - NLM
STAT- MEDLINE
DCOM- 20220208
LR  - 20220208
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 107
IP  - 5
DP  - 2021 Nov
TI  - Safety of outpatient stem cell mobilization with low- or intermediate-dose 
      cyclophosphamide in newly diagnosed multiple myeloma patients.
PG  - 566-572
LID - 10.1111/ejh.13693 [doi]
AB  - OBJECTIVES: Autologous stem cell transplantation is the gold standard for 
      eligible newly diagnosed multiple myeloma patients. Patients are usually 
      hospitalized for administration of mobilization chemotherapy. We aimed to assess 
      safety and efficacy of mobilization therapy with low-dose (2 g/m(2) ) and 
      intermediate-dose (3-4 g/m(2) ) cyclophosphamide administered as outpatient. 
      METHODS: A total of 176 consecutive newly diagnosed transplant-eligible myeloma 
      patients receiving outpatient mobilization were retrospectively evaluated. 
      Induction therapy was mainly performed with new drugs (91%). RESULTS: 
      Chemotherapy was very well tolerated with 16.6% of patients having all-grade 
      adverse events (AEs) and only 1.2% having severe AEs. The most frequently 
      reported AEs were nausea and vomiting grade 1-2 (6.8%). Only 5.7% of patients 
      required hospitalization for AEs. Stem cell collection was successful in 93.1% of 
      patients, with a median CD34(+) harvest of 8.7 x 10(6) /kg. Target for 2 
      autologous stem cell transplantation (at least 6 CD34(+)  x 10(6) /kg) was 
      reached by 76.3% of patients. Administration of plerixafor on demand was 
      necessary in 12.1% of patients. CONCLUSIONS: Outpatient mobilization with low- 
      and intermediate-dose cyclophosphamide appears an efficient and safe procedure, 
      with minimal and manageable AEs and low rate of hospitalization.
CI  - (c) 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Pompa, Alessandra
AU  - Pompa A
AD  - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Pettine, Loredana
AU  - Pettine L
AD  - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Giannarelli, Diana
AU  - Giannarelli D
AD  - Bio-statistical Unit, Regina Elena National Cancer Institute IRCCS, Rome, Italy.
FAU - Paris, Laura
AU  - Paris L
AD  - Hematology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
FAU - Torretta, Lorella
AU  - Torretta L
AD  - Transfusion Medicine and Cell Therapy Unit, Fondazione IRCCS Ca' Granda Ospedale 
      Maggiore Policlinico, Milan, Italy.
FAU - Cavallaro, Francesca
AU  - Cavallaro F
AD  - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Levati, Giorgia Virginia
AU  - Levati GV
AD  - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Stefanoni, Paola
AU  - Stefanoni P
AD  - Hematology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
FAU - Mocellin, Cristina
AU  - Mocellin C
AD  - Transfusion Medicine and Cell Therapy Unit, Fondazione IRCCS Ca' Granda Ospedale 
      Maggiore Policlinico, Milan, Italy.
FAU - Galli, Monica
AU  - Galli M
AD  - Hematology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
FAU - Baldini, Luca
AU  - Baldini L
AD  - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
AD  - University of Milan, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210804
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Alkylating/administration & dosage/*therapeutic use
MH  - Cyclophosphamide/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hematopoietic Stem Cell Mobilization/*adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/drug therapy/*therapy
MH  - *Outpatients
OTO - NOTNLM
OT  - mobilization chemotherapy
OT  - multiple myeloma
OT  - outpatient
OT  - safety
EDAT- 2021/07/24 06:00
MHDA- 2022/02/09 06:00
CRDT- 2021/07/23 17:25
PHST- 2021/07/17 00:00 [revised]
PHST- 2021/04/07 00:00 [received]
PHST- 2021/07/20 00:00 [accepted]
PHST- 2021/07/24 06:00 [pubmed]
PHST- 2022/02/09 06:00 [medline]
PHST- 2021/07/23 17:25 [entrez]
AID - 10.1111/ejh.13693 [doi]
PST - ppublish
SO  - Eur J Haematol. 2021 Nov;107(5):566-572. doi: 10.1111/ejh.13693. Epub 2021 Aug 4.